Skip to content
MedsAcross

Medicine

Cystaran 6.5 mg/mL ophthalmic solution

Cysteamine · Ophthalmic · Leadiant Biosciences
Available on requestPrescription onlyUS FDA Cold chain

Cystaran 6.5 mg/mL ophthalmic solution is a prescription medicine containing Cysteamine for ophthalmic use, marketed by Leadiant Biosciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Cold chain

Store unopened bottle in freezer at -25°C to -15°C (-13°F to 5°F) in the…

Key facts

Active ingredient (INN)
Cysteamine
Brand
Cystaran
Strength
6.5 mg/mL
Dosage form
Ophthalmic solution
Route
Ophthalmic
Packs
15 mL
Marketing authorisation holder
Leadiant Biosciences
Manufacturer
Leadiant Biosciences
Origin register
US FDA, United States
Storage
Store unopened bottle in freezer at -25°C to -15°C (-13°F to 5°F) in the original packaging including unopened foil. The thawed bottle does not require refrigeration between use. Store thawed bottle at 2°C to 25°C (36°F to 77°F) for up to 1 week.
Cold chain
Yes, shipped temperature controlled
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
A16AA04 Mercaptamine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
30 December 2012
Identifiers
RxCUI 1313780, 1313785DailyMed set ID b98ee838-ed23-42a9-93b5-72579e490fbaNDC 54482-035, 54482-020Application NDA200740

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
15 mL in 1 bottle54482-020-02Leadiant Biosciences25 February 2022
15 mL in 1 bottle54482-035-02Leadiant Biosciences25 April 2025

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 15 August 1994Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Cysteamine

Clinical summary

Cysteamine is a cystine depleting agent indicated for the management of nephropathic cystinosis in children and adults. It is available as ophthalmic solution, capsules and delayed-release capsules for oral use. MedsAcross supplies Cysteamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Cysteamine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Cystaran 6.5 mg/mL ophthalmic solution for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.